老年头颈鳞癌的治疗方式、不良事件与生存结局
基于SEER-Medicare数据库的原发性头颈鳞癌回顾性研究,比较不同治疗与年龄组的总生存和不良事件。在全部5879例及≥80岁组1380例中,放化疗较单纯放疗均与更好OS相关(HR=0.82,p<0.001;HR=0.77,p=0.006),且最年长组不良事件率不高于66-69岁组。
要点
- 放化疗较单纯放疗与更好OS相关,最年长组亦如此。
- ≥80岁组不良事件率不高于66-69岁组。
- 年轻组放化疗使用比例(26%-30%)高于最年长组(14%-19%)。
核心结论
- 放化疗较单纯放疗与老年头颈鳞癌患者更好OS相关,最年长组亦如此。
- 选择最佳治疗应同等考虑患者特征而非仅按实际年龄。
研究设计与样本
- 回顾性队列研究,数据来自SEER-Medicare关联数据库的原发性头颈鳞癌病例。
- 按四个年龄组分析,包括最年轻组66-69岁和最年长组≥80岁。
主要发现
- 全部患者(N=5879)中,放化疗较单纯放疗与更好OS相关(HR=0.82,p<0.001)。
- 最年长组(N=1380)中,放化疗较单纯放疗与更好OS相关(HR=0.77,p=0.006)。
- 最年长组不良事件率不高于最年轻组(N=1562)。
- 最年轻组接受放化疗比例(26%-30%)高于最年长组(14%-19%),与合并症指数无关。
临床怎么用
- 老年头颈鳞癌选择治疗时,应综合评估患者特征,不应仅依据实际年龄。
- 对≥80岁患者,放化疗可与更好OS相关且不良事件率未高于较年轻组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chemoradiation with curative intent in older adults with locally advanced head and neck squamous cell carcinoma (HNSCC) has been a challenge, because of its potential toxicities. METHODS: We selected primary HNSCC cases from the SEER-Medicare linked database, assessed overall survival (OS) and adverse events and their associations with different treatments, across four age groups including the youngest (66-69 years) and the oldest (≥80 years). RESULTS: Better OS was associated with chemoradiation compared to radiation alone, not only in all patients (N = 5879) (hazard ratio [HR] = 0.82, p < 0.001), but also in the oldest group (N = 1380) (HR = 0.77, p = 0.006) in whom the adverse events rates were not higher than those in the youngest (N = 1562); more of the latter (26%-30%) than the former (14%-19%) received chemoradiation, regardless of their comorbidity indices. CONCLUSIONS: Our findings provide evidence that patients' characteristics, other than chronological age, should be equally considered in selecting the best therapy for older patients with HNSCC.
引用
- Amr S, Ioffe D, Suzuki I, et al. Treatment modalities, adverse events, and survival outcomes in older patients with head and neck squamous cell carcinoma. Head Neck. 2021. PMID: 34632677. doi:10.1002/hed.26893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。